Log in

NASDAQ:AGLEAeglea Bio Therapeutics Stock Price, Forecast & News

$9.04
+0.11 (+1.23 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.87
Now: $9.04
$9.11
50-Day Range
$5.29
MA: $7.24
$9.06
52-Week Range
$3.50
Now: $9.04
$9.38
Volume134,609 shs
Average Volume217,847 shs
Market Capitalization$403.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocysteine; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
Aeglea Bio Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.06 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.89 million
Book Value$2.07 per share

Profitability

Net Income$-78,250,000.00

Miscellaneous

Employees61
Market Cap$403.09 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions

How has Aeglea Bio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aeglea Bio Therapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGLE stock has increased by 68.0% and is now trading at $9.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aeglea Bio Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aeglea Bio Therapeutics.

When is Aeglea Bio Therapeutics' next earnings date?

Aeglea Bio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aeglea Bio Therapeutics.

How were Aeglea Bio Therapeutics' earnings last quarter?

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.08. View Aeglea Bio Therapeutics' earnings history.

What price target have analysts set for AGLE?

3 Wall Street analysts have issued 1-year price objectives for Aeglea Bio Therapeutics' stock. Their forecasts range from $11.00 to $17.00. On average, they anticipate Aeglea Bio Therapeutics' share price to reach $13.33 in the next year. This suggests a possible upside of 47.5% from the stock's current price. View analysts' price targets for Aeglea Bio Therapeutics.

What are Wall Street analysts saying about Aeglea Bio Therapeutics stock?

Here are some recent quotes from research analysts about Aeglea Bio Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. " (5/5/2020)
  • 2. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development." (6/3/2019)

Has Aeglea Bio Therapeutics been receiving favorable news coverage?

Press coverage about AGLE stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAeglea Bio Therapeutics.

Are investors shorting Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 235,700 shares, a decline of 12.3% from the April 15th total of 268,900 shares. Based on an average daily trading volume, of 69,500 shares, the short-interest ratio is currently 3.4 days. Approximately 0.9% of the company's shares are short sold. View Aeglea Bio Therapeutics' Current Options Chain.

Who are some of Aeglea Bio Therapeutics' key competitors?

What other stocks do shareholders of Aeglea Bio Therapeutics own?

Who are Aeglea Bio Therapeutics' key executives?

Aeglea Bio Therapeutics' management team includes the following people:
  • Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)
  • Mr. Charles N. York II, CFO & VP (Age 42)
  • Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)
  • Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)
  • Mr. Eugene Sackett, VP of HR

When did Aeglea Bio Therapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea Bio Therapeutics' stock symbol?

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea Bio Therapeutics' major shareholders?

Aeglea Bio Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.55%), Soleus Capital Management L.P. (1.84%), State Street Corp (1.62%), Geode Capital Management LLC (1.09%), Ritholtz Wealth Management (0.77%) and Bank of New York Mellon Corp (0.33%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart and Anthony G Quinn. View institutional ownership trends for Aeglea Bio Therapeutics.

Which institutional investors are selling Aeglea Bio Therapeutics stock?

AGLE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., P.A.W. Capital Corp, Squarepoint Ops LLC, Ritholtz Wealth Management, JPMorgan Chase & Co., Two Sigma Investments LP, BlackRock Inc., and Deutsche Bank AG. View insider buying and selling activity for Aeglea Bio Therapeutics.

Which institutional investors are buying Aeglea Bio Therapeutics stock?

AGLE stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Wells Fargo & Company MN, SG Americas Securities LLC, Alliancebernstein L.P., State Street Corp, Geode Capital Management LLC, Franklin Street Advisors Inc. NC, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Aeglea Bio Therapeutics.

How do I buy shares of Aeglea Bio Therapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aeglea Bio Therapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $9.04.

How big of a company is Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics has a market capitalization of $403.09 million and generates $3.89 million in revenue each year. The biotechnology company earns $-78,250,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.

What is Aeglea Bio Therapeutics' official website?

The official website for Aeglea Bio Therapeutics is www.aegleabio.com.

How can I contact Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.